406 results about "Fusion gene" patented technology

The invention discloses a graph convolution spatial domain identification method of a fusion gene interaction network, and relates to the technical field of biological information, and the method comprises the steps: preprocessing spatial transcriptome data; constructing a spatial diagram according to the spatial position information of the spot and the gene expression matrix; constructing a conditional gene interaction network based on at least a part of key genes in the spatial transcriptome data, constructing a conditional gene interaction network matrix, combining the conditional gene interaction network matrix and the gene expression matrix to obtain an expression degree-interaction matrix, and constructing a feature map; performing graph neural network convolution on the space graph and the feature graph, and introducing an attention mechanism to obtain final embedding; and clustering and finally embedding, and identifying a spatial domain with a similar gene expression mode. According to the method, the spatial domain is identified through the fusion gene interaction network, the problem that the spatial domain is discontinuous is effectively solved, the robustness and accuracy of the spatial domain identification method are improved, and high performance is shown in complex and highly heterogeneous tissue samples.

The invention relates to the technical field of spatial transcriptome data clustering analysis, and discloses a spatial transcriptome data clustering method based on progressive learning and multi-modal fusion. According to the method, a high-order structure relationship among sample points is captured by using a multilayer graph convolutional network, and various noises of gene expression data are removed to the greatest extent through comparative learning and a complementary mask mechanism; meanwhile, gene expression data, spatial position information and histological image information are ingeniously fused to the maximum degree through two times of cross attention, and then fusion feature latent representation Latent is obtained. Compared with a mainstream spatial transcriptomics clustering analysis method, the method has the advantages that clustering based on the fusion feature latent representation Latent shows higher capability and excellent clustering performance, and has remarkable robustness.

According to the invention, the primers are designed for 65 leukemia fusion genes through sufficient literature investigation in the early stage, the leukemia genotypes covering 90% or more are covered, and the primers are good in amplification performance and strong in specificity; based on a multiple digital PCR system of an innovative multicolor fluorescent channel, different fluorescently-labeled hydrolysis probes are designed, multi-gene multi-channel detection is combined, 65 leukemia fusion genes are detected at the same time, leukemia typing can be judged through one-time detection, and time is saved. Through high-throughput detection, the cost is reduced to 1 / 10 of that of foreign like products, and the sensitivity is high.

The invention provides a kit and a method for detecting common fusion genes of lymphoid leukemia based on a multiple digital PCR (Polymerase Chain Reaction) method. By constructing a synergistic effect mechanism of the primer and the fluorescent probe and optimizing matching of the primer, the probe and a fluorescent marker, non-specific binding among amplification products is effectively avoided. A composite reaction aid with a specific formula, namely a PCR enhancer, is innovatively introduced, so that the amplification efficiency and specificity of a multiple detection system are remarkably improved. According to the kit provided by the invention, the integrated detection capability on seven fluorescent channels, namely Atto 425, VIC, FAM, ROX, CY5, CY5.5 and CY7, is realized in a single-hole design. By innovatively constructing an ROX + CY5 and Atto425 + VIC dual-channel joint detection system, when the ROX and CY5 channels or Atto425 and VIC channels in the same detection hole simultaneously present positive signals, two additional detection targets can be specifically interpreted. The innovative detection strategy based on channel combination enables the kit to realize precise detection of 18 fusion genes only through two detection holes in a breakthrough manner.

The invention relates to the field of intelligent medical treatment, in particular to a new antigen screening method, equipment and a program product. Comprising the following steps: S1, acquiring tumor slice data and serum data of a patient; s2, performing data processing on the tumor slice data and the serum data to obtain an HLA / MHC pseudo sequence, antigen peptide data and an antigen gene expression level; the data processing comprises data sequencing, HLA / MHC typing, somatic mutation calculation, fusion gene calculation and gene expression profile calculation; s3, screening new antigens based on the HLA / MHC pseudo sequence, the antigen peptide data and the antigen gene expression level data to obtain the new antigens, the application can perform new antigen screening, and has good clinical value.

The invention relates to the technical field of biology, in particular to a preparation method and application of a recombinant human long-acting interleukin-22 binding protein. The amino acid sequence of the recombinant human long-acting interleukin-22 binding protein is as shown in SEQ ID No. 1. According to the method for preparing the IL-22BP recombinant protein with high biological activity by utilizing an Escherichia coli prokaryotic expression system, a novel fusion protein is designed, a sequence for coding human IL-22BP is connected with a sequence for coding ABD to construct an IL-22BP-ABD fusion gene, the IL-22BP-ABD fusion gene is induced to be expressed in Escherichia coli, inclusion body protein is separated, and the IL-22BP recombinant protein with high biological activity is obtained. The target protein is obtained through denaturation, purification and renaturation, and the biological activity of the IL-22BP-ABD is verified through in-vivo and in-vitro experiments.

The invention relates to the technical field of plant genetic engineering, in particular to a ginkgo GbGRF2 gene and application of a GbGRF2-GbGIF2 fusion gene of the ginkgo GbGRF2 gene in plant tissue culture. According to the invention, the GbGRF2 gene coding region full length of the GRF gene family of gingko is successfully cloned from gingko, and the gene presents a specific expression mode in the regeneration process of gingko callus; the overexpression of the fusion gene of GbGRF2 and GbGRF2-GbGIF2 can significantly promote the regeneration efficiency of adventitious buds in the in-vitro culture process of plants; the gene provided by the invention has important theoretical significance and application potential in a plant tissue regeneration regulation network, and plays a key role in improving in-vitro regeneration efficiency of gymnosperm.

The invention discloses a bifluorescence in-situ imaging fusion gene method and a kit, and belongs to the technical field of bioengineering, the kit comprises a first primer pair for detecting an e13a2 subtype, an amplification probe T1, an amplification probe T2, a molecular beacon probe MB1 and a molecular beacon probe MB2; the first primer pair is used for detecting the e14a2 subtype, the second primer pair is used for detecting the e14a2 subtype, and the amplification probe T1, the amplification probe T3, the molecular beacon probe MB1 and the molecular beacon probe MB3 are used for detecting the e14a2 subtype; the first primer pair comprises H1-1 and H2, and nucleotide sequences of the H1-1 and the H2 are respectively shown as SEQ ID NO.1-2; the second primer pair comprises H1-2 and H3, and the nucleotide sequences of the H1-2 and H3 are respectively shown as SEQ ID NO.3-4; the nucleotide sequences of the amplification probe T1, the amplification probe T2 and the amplification probe T3 are respectively as shown in SEQ ID NO.5-7; and the nucleotide sequences of the molecular beacon probes MB1, MB2 and MB3 are respectively as shown in SEQ ID NO.8 to SEQ ID NO.10. By means of the mode, in-situ imaging of the BCR / ABL P210 subtype can be achieved, and operation is easy, convenient and rapid; meanwhile, the quantity information of the residual tumor cells can be reflected, and the tumor cells which are as low as 0.01% can be detected.

The present invention relates to the technical field of fusion gene detection, and in particular to a TTMV::RARA fusion gene analysis method based on transcriptome sequencing. The present invention adopts sequencing data comparison, CLIP event determination, fusion sequence assembly, and fusion sequence identification, and finally achieves the purpose of assembling and identifying the TTMV::RARA fusion gene. Among them, all TTMV genome sequences in known databases are collected as reference sequences, which can achieve the maximum identification detection rate and accuracy. The assembled sequence contains relatively conservative regions of the TTMV genome, so that highly variable TTMV sequences can also be identified and detected. Finally, the TTMV::RARA fusion gene analysis method based on transcriptome sequencing in the present invention is guaranteed to be fast, sensitive, and accurate.

The invention provides a method for preparing rebaudioside M by constructing a UGT91C1-UGT76G1-SuSy fusion enzyme on the basis of an artificially constructed substrate microchannel principle and using relatively cheap raw materials to efficiently catalyze a cascade reaction. EAAAK 3 and (GGGGS) 4 are used as connecting peptides, UGT76G1 is fused at the C end of UGT91C1, SuSy is fused at the C end of UGT76G1, mass transfer of an intermediate product is enhanced, and the intermediate product is prevented from being diffused to a reaction main body. The invention also discloses a construction method of the ugt91C1-C1-ugt76G1-suusy fusion gene, a construction method of a recombinant plasmid, a construction method of a recombinant strain, a protein expression and purification method and a method for catalytically preparing a product. The ugt91C1-C1-ugt76G1-suusy fusion gene has a very good application prospect in biological industrial catalytic production.

The invention relates to the technical field of aquaculture fish vaccines, in particular to a fusion gene of grass carp NPM1a and II type reovirus VP38, recombinant protein, a composition and application. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1. The fusion gene is obtained by connecting grass carp NPM1a and II type reovirus VP38 through a linker sequence, a BamH restriction enzyme cutting site is added to the 5'end of the fusion sequence, and an XhoI restriction enzyme cutting site is added to the 3 'end of the fusion sequence; the sequence of the linker is as shown in SEQ ID NO: 2. The subunit vaccine of the fusion protein of the grass carp NPM1a and the II type reovirus VP38 is prepared, and indole-3-lactic acid is used as an immunopotentiator in a combined manner, so that the technical bottlenecks of low protection rate, poor intestinal mucosal barrier repairability and the like of the existing vaccine are overcome.

The invention discloses a method for evaluating the detection effect of a fusion gene detection method, and belongs to the technical field of evaluation based on the detection effect. According to the invention, a detection reference substance I and a detection reference substance II are constructed, and the detection reference substances are connected with a reference gene segment in equal molecular number proportion, so that the detection condition under the condition of equivalent reference gene expression level can be realized, and whether the sample quality reaches the detection standard or not can be deduced; the measurement of the lowest detection quantity of the fusion gene relative to the expression quantity of the reference gene is realized; the first detection reference is used for detecting sensitivity analysis of the fusion type by the detection method of the fusion gene to be detected, and the second detection reference is used for verifying whether a detection result of the detection method of the fusion gene to be detected is a false negative result or not. And the method has a very good application prospect.

The invention belongs to the technical field of biology, particularly relates to a detection method of an RNA fusion gene, and more particularly relates to a detection method of an RNA fusion gene based on an FFPE sample source. According to the method, the total RNA is used as a template to build the library, and the step of enriching mRNA or removing rRNA is not needed, so that the experiment time is shortened, and the experiment cost is reduced; according to the invention, a quality control index DV200 of sample RNA and grade division of the sample are provided, so that more accurate library construction of subsequent samples with different quality grades is facilitated; the internal reference quality control product is added in the whole experiment, so that the whole experiment process is better monitored, and the experiment accuracy is improved.

The invention discloses an escherichia coli engineering bacterium for producing 5-ALA by an anaerobic fermentation method as well as a construction method and a fermentation method of the escherichia coli engineering bacterium. The engineering bacterium is constructed by taking escherichia coli (E. coli) ZX11 as a host and performing heterologous expression on 5-ALA synthetase (HemA) from rhodobacter capsulatus. In order to improve the soluble expression level of the HemA, the HemA is subjected to fusion expression with a maltose binding protein (MBP) tag. Furthermore, the engineering bacterium can also heterologously express a visual purple protein (PR) fused with the MBP tag. The construction method of the engineering bacteria comprises the following steps: sequentially cloning the MBP-HemA fusion gene and the PR gene to an expression vector and transferring into host bacteria. By utilizing the engineering bacteria provided by the invention, anaerobic fermentation can be carried out in a culture medium taking glucose as a carbon source, and 5-ALA can be efficiently synthesized. The invention provides an effective way for realizing green and energy-saving anaerobic biological manufacturing of 5-ALA.

The invention discloses a rapid detection method for traumatic brain injury by fusing genetic engineering and quantum dots, and relates to the technical field of traumatic brain injury detection. The method comprises the following steps: acquiring a suspected patient biological sample, extracting biomolecule components, and comparing the biomolecule components with a healthy population biomolecule database to obtain related differential expression molecules. A specifically recognizable recombinant antibody is constructed by genetic engineering, and is connected with a quantum dot through a coupling reaction to prepare a detection probe. The probe and a biological sample are mixed and reacted, and the intensity of a fluorescence signal generated by combination is collected by a fluorescence detection device. A standardized signal value is obtained through signal processing algorithm noise reduction and feature extraction, and a preliminary detection result is determined by combining a bioinformatics database evaluation sample. And finally, according to the differential expression molecule, the standardized signal value and the preliminary result, analyzing a data change trend in a preset time window by using a multivariable statistical model, and generating a diagnosis report. According to the method, various technologies are fused, and a new path is provided for traumatic brain injury detection.

The invention provides a multi-stream fusion gene sequence prediction method based on Mama and a double-coding strategy, and aims to improve semantic understanding and modeling capability of DNA sequences, so as to improve accuracy and generalization performance of protein expression value prediction. The method comprises the following steps: synchronously processing a forward chain and a reverse complementary chain of a DNA sequence: carrying out word segmentation and vectorization on the reverse complementary chain by adopting BPE coding to capture a semantic fragment; and the forward chain is subjected to one-hot coding and is linearly mapped into dense representation. Deep features of the two features are extracted through Mama Block and then are spliced and fused, then LSTM is input to model context dependence, and finally an expression value is output through a full connection layer. According to the method, the problems that biological semantic fragments are difficult to capture by One-Hot coding and functional domains are likely to be split by BPE coding are effectively solved. On the basis of a Mama framework, a local structure and global semantics are effectively combined, and the method is good at capturing long-distance dependence while low calculation complexity is kept, and is suitable for tasks such as gene design and protein expression regulation and control.

The invention discloses a blood tumor fusion gene minimal residual focus monitoring method, system and equipment, and the key points of the technical scheme are as follows: obtaining fusion gene information and high-throughput sequencing data of all genetic information; under the condition that the high-throughput sequencing data is subjected to PCR without duplicate removal, comparing the high-throughput sequencing data to a reference genome to obtain a first comparison result, screening out a real fusion gene sequence from the first comparison result, and calculating to obtain a first copy number of a fusion gene according to the real fusion gene sequence; a real housekeeping gene sequence is screened out from the first comparison result, and a second copy number of housekeeping genes is calculated according to the real housekeeping gene sequence; dividing the first copy number by the second copy number to obtain the minimal residual focus ratio of the fusion gene. According to the invention, high-sensitivity and high-specificity monitoring of MRD can be realized.

The utility model is suitable for the technical field of diagnostic kits, and provides a low-grade endometrial interstitial sarcoma diagnostic kit. The low-grade endometrial interstitial sarcoma diagnostic kit comprises a kit body and a kit cover, the kit body comprises a first unit and a second unit; the first unit is provided with a test tube box containing RNase-Free water, a test tube box containing 2 * qPCR Mix and a test tube box containing a 5 * all in one reverse transcription reagent; the second unit is provided with a test tube box containing an internal standard primer, a test tube box containing a JAZF1-SUZ12 primer and a test tube box containing a positive cDNA standard substance. According to the utility model, the JAZF1-SUZ12 fusion gene can be detected, and the JAZF1-SUZ12 fusion variation has specificity and exclusiveness in the LGESS, so that the JAZF1-SUZ12 fusion gene detection kit has very high value for differential diagnosis of the LGESS; an RT-qPCR method is adopted, whether the fusion gene exists in a patient sample or not is judged according to whether a positive signal exists in a reaction tube or not and a ct value of qPCR or not, the method is rapid, simple and convenient, and no operation is needed after the PCR reaction.

The present invention relates to a drug, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, a drug for inhibiting drug resistance, a method for screening patients, and the like for ALK fusion gene-positive cancer, which has positive expression of FGFR1 and positive expression of FGF2, and which is obtained by combining a compound having ALK inhibitory activity with an FGFR inhibitor. The present invention also relates to a drug, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, or a drug for inhibiting drug resistance, a method for screening patients, and the like.

The invention relates to an expression cassette and a method for producing humanized triple helix collagen by using the expression cassette, and belongs to the technical field of genetic engineering. The expression cassette sequentially comprises a promoter sequence, a fusion gene and a terminator sequence from upstream to downstream, the fusion gene comprises nucleotide fragments A, B and C, each fragment comprises an immutable region and a variable region, and the variable region is selected from I, II, III, IV and XVII type human collagen. A kex2 protease recognition site KR is introduced into an expression box, so that an expression product can be subjected to trisection cutting, and three equal-length peptide chains with a triple-helix basic structure are formed. The invention also provides a recombinant humanized collagen with a self-assembled triple helix structure and a production method thereof, and the method comprises the following steps: preparing a recombinant expression vector containing the expression cassette and a proline hydroxylase expression vector, and transferring the two expression vectors into competent cells for co-expression. The method can be used for producing the recombinant humanized collagen with the self-assembled triple-helix structure, and has a good application prospect.

The invention discloses a KMT2A fusion gene detection primer probe group, a kit and a detection method, the primer probe group is specifically designed based on KMT2A gene fusion and 13 common partner genes MLLT3, AFF1, MLLT10, MLLT1, MLLT4, ELL, EPS15, SEPT6, MLLT11, MLLT6, SEPT9, AFF3 and CBL fusion sites, the mutual interference is small, the primer probe group can be used for targeted amplification of a fusion gene specific region in a single-tube mixed solution, the detection sensitivity is high, the detection time is short, the detection time is short, and the detection efficiency is high. According to the present invention, the rapid detection of any one fusion gene type in 67 types can be achieved, and compared with the high-throughput sequencing, the sensitivity is high, the detection rate is high, the single sample detection cost is low, the method is suitable for the clinical auxiliary diagnosis of the large batch of samples, and the guidance is provided for the diagnosis, the treatment and the prognosis of the blood disease patients.

The invention relates to the field of cell biology, and discloses an exosome for displaying BMP7 on the surface as well as a preparation method and application of the exosome. The preparation method comprises the following steps: constructing a fusion gene containing a glycosylation sequence, an HA tag, a BMP7 gene, a Lamp2b gene and a connecting sequence, and the nucleotide sequence of the fusion gene is as shown in SEQ ID NO.1; inserting the fusion gene into an expression cassette of an expression vector to obtain a recombinant expression vector; transferring the recombinant expression vector into a cell which generates the exosome, and screening to obtain a stable BMP7-Lamp2b overexpression cell; and culturing the BMP7-Lamp2b overexpressed cells, collecting the supernatant of the cell culture medium, and purifying to obtain the exosome with the surface displaying BMP7. The prepared exosome with the surface displaying BMP7 can improve the medicine utilization rate and the action time, reduce the medicine use concentration and use frequency, finally reduce the production cost and reduce the infection risk caused by articular cavity injection.

The invention discloses a pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector as well as a construction method and application of the pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector. The construction method comprises the following steps: mixing an mCherry gene segment and an IRES2 gene segment which are respectively obtained by PCR (Polymerase Chain Reaction) amplification in equal mass, then carrying out fusion amplification to obtain an IRES2-mCherry fusion gene segment, and carrying out homologous recombination on the IRES2-mCherry fusion segment and a pCDNA-3xHA-hTERT linearization vector. On the basis of a pCDNA-3xHA-hTERT stent vector, a pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector with red fluorescence is successfully constructed, and the fusion expression vector can be used as a fusion expression vector of the pCDNA-3xHA-hTERT-IRES2. The construction method is simple and efficient, enzyme digestion is not needed, and the constructed pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector can be subsequently used for transfecting bovine endometrial epithelial cells, so that the immortalized bovine endometrial epithelial cells are obtained.

The invention relates to the technical field of gene engineering, in particular to construction and application of a fusion gene for coding a green fluorescence labeled nerve growth factor fusion protein with biological activity. The nucleotide sequence of the fusion gene and the amino acid sequence of the fusion protein are respectively shown as SEQ ID No.1 and SEQ ID No.2. The invention also relates to methods for constructing an expression plasmid containing the nucleotide sequence of the fusion gene, preparing a virus vector and the like. The fusion gene can be expressed into a nerve growth factor fusion protein with green fluorescence in cells cultured in vitro and animal bodies, so that the expression and distribution of the fusion gene in the cells and tissues can be directly observed under a fluorescence microscope, and the fusion protein still has the biological activity of the nerve growth factor. The nerve growth factor in the fusion protein can be accurately metered by measuring the fluorescence intensity of the fusion protein or the content of the fusion protein.

The invention belongs to the field of escherichia coli metabolic processes, and particularly relates to a method for producing D-psicose from escherichia coli through glucose fermentation. Escherichia coli is used as a chassis host bacterium, a pgi gene, an SUMO-alsE fusion gene and an a6PP gene are subjected to overexpression at the same time, then a pfkA gene, a pfkB gene and a rpiA gene are knocked out in sequence, and a recombinant bacterium capable of producing D-psicose through glucose fermentation is obtained; the recombinant bacteria are used for fermentation, and glucose is converted to generate D-psicose.

The invention relates to an astroblastoma (ABM) cell model as well as a construction method and application thereof. The astroblastoma cell model is a human induced neural progenitor cell which carries and can express MN1: BEND2 and / or MN1: CXXC5 fusion genes, has the molecular phenotype and proliferation characteristics of MN1 fusion gene mutant ABM tumors, can still well simulate the characteristics of the ABM tumors when transplanted into animal brains, and can be used for preparing the astroblastoma cell model. Therefore, an important research tool is provided for mechanism research and drug development of ABM tumors.

The invention discloses a primer combination for detecting various gene mutation types, a library construction method and application thereof. A specific primer combination system is designed and can be effectively applied to construction of detection libraries of various gene mutation types, and random primers, template replacement primers and random primers carrying universal sequences are utilized; fixed sequences are respectively added at the 3'end and the 5 'end of the cDNA subjected to reverse transcription, so that a target fragment is amplified by a 3' / 5 'gene specific primer and a universal primer, fusion forms of the 5'end and the 3' end of a target gene can be detected at the same time, two types of fusion are amplified separately, mutual interference is reduced, and the accuracy and sensitivity of detection are improved; a DNA target fragment is amplified through a DNA specific primer pair and a universal primer, so that rapid and comprehensive detection of various types of variation in a target fusion gene and DNA can be realized, the operation is simple, the cost is low, and the audience range is wide.

The application relates to a sarcoma fusion gene nanopore sequencing primer set and application thereof, wherein the primer set comprises five pairs of specific primers (Primer 1-5) with fixed sequences, each primer follows the design principle of 18-25 bp in length, 40%-60% in GC content and strict matching of a target sequence at a 3' end, and the length of an amplification product is 300-800 bp, which is suitable for nanopore sequencing. Through qPCR verification, the primer set has single-peak melting curves, close-to-100% amplification efficiency, strong specificity and excellent amplification performance.

The invention relates to a rearrangement driven solid tumor fusion gene detection reagent, a kit and a detection system, belongs to the technical field of biological medicines, and provides a detection probe library, a detection reagent, a detection kit and a detection system for detecting a human solid tumor fusion gene. Probes in the probe library can be hybridized with one or more chromosome sites, and the total number of the sites is 11472; the detected solid tumors comprise rearrangement-driven solid tumors such as soft tissue tumors, uterine mesenchymal tumors or salivary gland tumors. The target RNA fusion gene detection reagent provided by the invention can be used for fusion gene detection at the RNA level, and has more advantages in the aspect of detection capability. The important significance is realized on the auxiliary diagnosis of solid tumors; according to the invention, multiple gene fusion forms can be detected at the same time, accurate diagnosis and treatment opportunities are provided for patients, and economic burden and additional risks caused by superposition of multiple markers are avoided.

The invention provides application of IGF2BP3 serving as a target spot in preparation of a medicine for treating fused genotype leukemia, and particularly relates to application of IGF2BP3 serving as a target spot in preparation of a medicine for treating mRNA (messenger ribonucleic acid) high-stability fused genotype leukemia. The mRNA high-stability fusion gene comprises but is not limited to fusion genes such as PAX5-ETV6, STK38-PXT1 and the like. The medicine comprises an IGF2BP3 gene specific interfering RNA (Ribonucleic Acid) and an IGF2BP3 inhibitor, and the IGF2BP3 inhibitor comprises but is not limited to Vitonetog. The invention provides the application of the medicine taking the IGF2BP3 as the target spot in treating mRNA high-stability fused genotype leukemia for the first time; the invention discloses the effect of the IGF2BP3 in the carcinogenic function of the fusion gene, provides a new therapeutic target and an effective drug for the fusion genotype leukemia, and provides possibility for further improving the clinical curative effect of leukemia patients and improving the prognosis and survival of the leukemia patients.